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Abstract
Background: The recent advent of murine leukaemia virus (MLV)-based replication-competent retroviral
(RCR) vector technology has provided exciting new tools for gene delivery, albeit the advances in vector
efficiency which have been realized are also accompanied by a set of fresh challenges. The expression of
additional transgene sequences, for example, increases the length of the viral genome, which can lead to
reductions in replication efficiency and in turn to vector genome instability. This necessitates efforts to
analyse the rate and mechanism of recombinant emergence during the replication of such vectors to
provide data which should contribute to improvements in RCR vector design.
Results: In this study, we have performed detailed molecular analyses on packaged vector genomes and
proviral DNA following propagation of MLV-based RCR vectors both in cell culture and in pre-formed
subcutaneous tumours in vivo. The effects of strain of MLV, transgene position and host cell type on the
rate of emergence of vector recombinants were quantitatively analysed by applying real-time PCR and real-
time RT-PCR assays. Individual mutants were further characterized by PCR, and nucleotide sequence and
structural motifs associated with these mutants were determined by sequencing. Our data indicate that
virus strain, vector design and host cell influence the rate of emergence of predominating vector mutants,
but not the underlying recombination mechanisms in vitro. In contrast, however, differences in the RNA
secondary structural motifs associated with sequenced mutants emerging in cell culture and in solid
tumours in vivo were observed.
Conclusion: Our data provide further evidence that MLV-based RCR vectors based on the Moloney
strain of MLV and containing the transgene cassette in the 3' UTR region are superior to those based on
Akv-MLV and/or containing the transgene cassette in the U3 region of the LTR. The observed
discrepancies between the data obtained in solid tumours in vivo and our own and previously published
data from infected cells in vitro demonstrates the importance of evaluating vectors designed for use in
cancer gene therapy in vivo as well as in vitro.
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Background
Retroviruses undergo a high frequency of recombination
events during replication of their genomes, leading to a
large number of variants or "quasispecies" in a viral pop-
ulation (reviewed in [1-5]). The majority of recombina-
tions arise during reverse transcription of the retroviral
RNA genome into proviral DNA by the retroviral reverse
transcriptase (RT), primarily during minus-strand DNA
synthesis, although the cellular RNA polymerase (RNAP)
II, which synthesizes the retroviral genome, has also been
demonstrated to introduce mutations into retroviral vec-
tor genomes at a very low frequency [6,7]. Not only does
the retroviral RT lack proof-reading activity, which leads
to a high rate of base misincorporations (reviewed in [8]
and [4]), but it also exhibits low processivity and fre-
quently dissociates from its RNA template, which can in
turn lead to template-switching both within the same
molecule (intramolecular recombination) [9-11] and
between the two co-packaged molecules of the viral RNA
dimer (intermolecular recombination) [12,13,12,14,15].
Retroviruses have been used for a wide variety of gene-
delivery applications in both pre-clinical and clinical stud-
ies, including the treatment of solid tumours [16,17].
Until recently, cancer gene therapy applications of retrovi-
ruses were restricted to the use of replication-deficient ret-
roviral (RDR) vectors, but, since it has emerged that
clinically beneficial transduction efficiencies are difficult
to achieve with non-replicating vectors [18,19], attention
has switched to the use of their replication-competent
counterparts. Replication-competent retroviral (RCR) vec-
tors based on murine leukaemia virus (MLV) have subse-
quently been shown to be powerful tools for gene transfer
both in cell culture [20-26] and in solid tumours in pre-
clinical studies [23,27-32].
A potential drawback with the use of RCR vectors, how-
ever, is that the expression of heterologous genes necessi-
tates the elongation of the viral genome beyond its natural
size, which can lead to a reduction in replication efficiency
[33]. Moreover, due to the propensity of retroviruses to
undergo recombination, deletion of heterologous
sequences may occur, leading to the generation of
mutants with increased replication efficiency relative to
the parental vector, and, if this difference is great enough,
the mutants will soon become dominant in a population
of replicating viruses. This is doubly problematic for the
success of gene therapeutic applications, since, not only
do these mutants no longer express the therapeutic gene,
but, due to superinfection resistance [34], cells infected
with recombinant vectors become refractory to subse-
quent infection with the parental vector. It is hence of par-
amount importance to analyse the selective pressure for
transgene deletion exerted on vectors of different design
and under different propagation conditions, to allow a
clear assessment of both the factors leading to the emer-
gence of predominating vector mutants and the recombi-
nation mechanisms associated with their generation.
The underlying molecular mechanisms resulting in indi-
vidual mutational and recombinatorial events have been
extensively investigated in replication-deficient retroviral
(RDR) vectors, but relatively few studies have investigated
RCR vectors in this respect. In contrast to studies with
RDR vectors, where recombination events taking place in
a single replication cycle are detected, during multiple rep-
lication cycles of RCR vectors mutations can accumulate
and individual mutations and deletions can be shuffled
among the vector population by interstrand recombina-
tion. However, only recombinants which provide a repli-
cation advantage over the parental vector will become
dominant in a population of replicating viruses, and
hence analyses of sequences flanking recombination junc-
tions of such vector mutants may provide information
useful for RCR vector design.
In a recent study, we reported that the efficacy of MLV-
based RCR vectors can be influenced not only by virus
strain and transgene position, but, interestingly, also by
the host cell [35]. In the present study, to shed more light
on the possible mechanisms behind these differences, we
have performed detailed molecular analyses on recom-
binants which emerged during vector replication both in
cell culture and in solid tumours in vivo. The rate of emer-
gence of vector mutants containing deletions in transgene
sequences was quantified, and the underlying nucleotide
sequence and structural motifs associated with the gener-
ation of such mutants were characterised.
Results
Propagation of MLV-based RCR vectors in vitro and in vivo
Very recently, data have been published unravelling the
effects of virus strain, transgene position and target cells
on the efficacy of Moloney (Mo)- or Akv-MLV-based RCR
vectors genetically pseudoptyped with the 4070A ampho-
tropic env gene, from which eGFP expression is mediated
by the EMCV IRES [35]. The results revealed that vectors
based on Mo-MLV and containing the IRES-eGFP cassette
precisely fused directly to the 3' end of the MLV 4070A env
gene replicate more efficiently and propagate a functional
eGFP-expression over a longer time period than analo-
gous vectors based on Akv-MLV, in which an identical
IRES-eGFP cassette is also precisely fused to the 3' end of
the MLV 4070A env gene, as well as Mo-MLV-based vec-
tors containing the same IRES-eGFP cassette in the U3
region of the LTR. Furthermore, both Mo- and Akv-MLV-
based vectors propagated eGFP expression for longer in
HEK293 cells than in NIH-3T3 or U87-MG cells, regard-
less of transgene position. The loss of eGFP expression was
presumably mediated by functional abrogation of theBMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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transgene cassette via recombination and/or point muta-
tions gathered during vector replication.
Here, in the present study, we performed detailed molec-
ular analyses to quantify the rate of the emergence of vec-
tor recombinants in populations of replicating MLV-
based vectors, and to characterise the underlying recombi-
nation mechanisms leading to the generation of these
mutants. The experimental design enabled each vector to
maintain exponential spread throughout the duration of
the experiment, as described previously [35]. Cells were
inoculated with vectors ACE-GFP [22], ACEU3-GFP,
Akv4070AeGFP or AkvB4070AeGFP [35] (Fig. 1) at an
MOI of 0.001, and subsequently passaged every 2 or 3
days. Four days post infection, virus-containing superna-
tant was harvested and used to inoculate fresh cells, using
a dilution factor resulting in infection levels of between
1% and 10%. This process was repeated for multiple serial
infection cycles. The emergence of vector recombinants in
solid tumours was investigated by infecting preformed
subcutaneous U87-MG xenografts growing in nude mice.
Detection and quantification of the emergence of vector 
recombinants in vitro and in vivo
The rate of emergence of vector recombinants lacking
transgene sequences which were packaged into viral parti-
cles was quantitatively determined via real-time RT-PCR
performed on RNA extracted from cell-free supernatants
of infected cells at the end of each infection cycle. The
emergence of vector mutants in vivo was quantified by
real-time PCR performed on DNA extracted from infected
tumours 5, 10, and 20 days following vector inoculation.
Primers and probes annealing either to a region in the env
gene or to a region in the IRES-eGFP transgene cassette
were used, allowing discrimination between vectors
which contain both env  and transgene sequences, and
those which contain the env coding region but no longer
contain the complete transgene sequence. In the case of
vector ACE-GFP replicating in NIH-3T3 cells, the ratio of
env to transgene signal begins to increase at infection cycle
9, but does not increase at all in HEK293 or U87-MG cells
infected with ACE-GFP (Fig. 2), indicating that no major
deletion mutants emerge in these cells. The ratio of env to
transgene signal in cells infected with vector ACEU3-GFP,
on the other hand, increases in each cell line analysed,
from infection cycles 5, 16, and 3 onwards in NIH-3T3,
HEK293 and U87-MG cells, respectively (Fig. 2). Simi-
larly, the ratio of env to transgene signal in cells infected
with vector Akv4070AeGFP or AkvB4070AeGFP also
increases in each cell line, albeit slightly later, from infec-
tion cycles 12, 19, and 12 onwards, in NIH-3T3, HEK293,
and U87-MG cells, respectively (Fig. 2). By analysing the
differences in the rate of increase of the ratio of env to
transgene signal, it is apparent that vector mutants emerge
most rapidly in cells infected with vector ACEU3-GFP,
and that this process occurs most slowly in cells infected
with vector ACE-GFP, except in NIH-3T3 cells. The rate of
emergence of vector mutants was slowest, regardless of
vector design or virus strain, when vectors were propa-
gated in HEK293 cells. Significant increase in the ratio of
env to transgene signal could not be detected in in vivo
infected tumours, indicating that the majority of all vec-
tors in the replicating virus population still contained the
transgene cassette, even following 20 days of in vivo prop-
agation (Fig. 2).
The real-time RT-PCR and real-time PCR assays allow the
exact quantification of the proportion of packaged vector
RNA or proviral DNA lacking transgene sequence ele-
ments obligatory for PCR amplification, but do not per-
mit the precise localisation and characterisation of
individual recombination events leading to the genera-
tion of such mutants. Thus, alterations in the transgene
cassette of vector mutants were detected by PCR of
genomic DNA extracted from infected cells at the end of
each infection cycle (Fig. 3A) and from infected tumours
5, 10, and 20 days following vector inoculation, as previ-
ously described [35] (Fig. 3B), using primers annealing to
sequences in the env gene and in the 3' LTR. With this
method, vector mutants which replicate more rapidly
than the parental vector, and which have thus accumu-
lated in the viral population, can be visualised as distinct
bands.
In cells infected with ACE-GFP, bands representing vector
recombinants were detectable following 17, 7, and 19
infection cycles of propagation in HEK293, NIH-3T3, and
U87-MG cells, respectively (Fig. 3A), whereby the bands
detectable in HEK-293 and U87-MG cells were much
MLV-based RCR vectors Figure 1
MLV-based RCR vectors. Moloney-MLV-based (ACE-
GFP, ACEU3-GFP, white vector backbone) and Akv MLV-
based (Akv4070AeGFP, AkvB4070AeGFP, grey vector back-
bone) vectors harbouring an IRES-eGFP transgene cassette 
either immediately downstream of the MLV 4070A env gene 
or inserted in the U3 region of the 3' LTR. A single amino 
acid was altered (Glu to Arg indicated by an asterisk) in the 
N-tropic vector Akv4070AeGFP to generate the B-tropic 
vector AkvB4070AeGFP, which can efficiently infect human 
cells.
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fainter than the bands representing parental vectors, indi-
cating that deletion mutants only made up a small pro-
portion of the replicating vector population. Bands
representing vector mutants were detectable in all cell
lines infected with vector ACEU3-GFP at a much earlier
time point, on the other hand, following 13, 4, and 3
infection cycles in HEK293, NIH-3T3 and U87-MG cells,
respectively (Fig. 3A), and, in each case, bands represent-
ing parental vectors became undetectable, indicating that
mutant vectors had become dominant in the replicating
vector population. Bands representing vector recom-
binants could be detected following 15, 9, and 11 infec-
tion cycles of vector AkvB4070AeGFP in HEK293 and
U87-MG cells, and of vector Akv4070AeGFP in NIH-3T3
cells, respectively (Fig. 3A), with a concomitant decrease
in the intensity of bands representing parental vectors also
indicating that mutant vectors had become dominant in
the replicating vector population. The accumulation of
vector mutants detectable by PCR in this assay reflects the
decrease in the ability of vectors to propagate a functional
transgene cassette, as was previously shown by FACS anal-
ysis [35], indicating that loss of eGFP-expression is prima-
rily due to recombination-mediated deletion and not to
point mutations. Taken together, the differences in the
appearance of bands representing mutant vectors indicate
that (i) vector recombinants predominating in the repli-
cating virus population emerge most rapidly in cells
infected with vector ACEU3-GFP, (ii) this process occurs
most slowly in cells infected with vector ACE-GFP, and
(iii) the rate of emergence of predominant vector mutants
was slowest, regardless of vector design or virus strain,
when propagated in HEK293 cells. In in vivo infected
Quantification of the rate of recombinant emergence by real-time PCR and real-time RT-PCR Figure 2
Quantification of the rate of recombinant emergence by real-time PCR and real-time RT-PCR. Viral RNA iso-
lated from cell-free medium supernatant of in vitro infected NIH-3T3, HEK293, and U87-MG cells and DNA isolated from in 
vivo infected subcutaneous U87-MG tumours growing in Hsd:athymic Nude-Foxn1nu mice was used to determine the ratio of 
viral- and transgene-specific sequences in the packaged vector genome and in integrated proviruses, respectively. Two sets of 
primers and probes were used for real time PCR and real time RT-PCR, one annealing to sequences in the env gene and the 
second to sequences in the IRES or the eGFP gene, respectively. Viral to transgene specific sequence ratios are shown at the 
end of each infection cycle for cell lines infected in vitro and 5, 10, and 20 days post infection of solid tumours in vivo, respec-
tively. Error bars represent the standard deviation of the viral to transgene ratios measured in infected solid tumours excised 
from 5 mice sacrificed at each time point.
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Figure 3 (see legend on next page)
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tumours, bands representing vector mutants were infre-
quently detected except in tumours excised 20 days fol-
lowing infection with vector ACEU3-GFP (Fig. 3B), and,
even here, bands representing parental vectors were also
of similar intensity, indicating that deletion mutants had
not become dominant in the vector population. As in
infected cell cultures, it is apparent that the rate of emer-
gence of predominant vector mutants was slowest in
tumours infected with vector ACE-GFP and most rapid in
tumours infected with vector ACEU3-GFP. Although sev-
eral distinct bands could be detected corresponding to
vector mutants which contained deletions of different
sizes, no discernable pattern or trend regarding the size of
the deletion mutants was revealed, and hence there seems
to be no influence of the virus strain, transgene position,
or host cell in this respect.
Molecular mechanism of the emergence of vector 
recombinants
To evaluate the role of previously described molecular
determinants of retroviral recombination such as the
prevalence of nucleotide sequence similarity [36,37] and
RNA secondary structure [38-40,67] on the generation of
vector recombinants which emerged in the replicating
virus population, a total of 29 PCR products, representing
the majority of vector recombinants which were detecta-
ble by PCR analyses, were excised from agarose gels and
sequenced. Vector recombinants were classified with
respect to the parental vector, the host cell line or tumour
Detection of deletion mutants by PCR Figure 3 (see previous page)
Detection of deletion mutants by PCR. Primers annealing to MLV 4070A env and LTR U3 specific sequences were used 
to amplify integrated proviral vector DNA isolated from (A) in vitro infected NIH-3T3, HEK293, and U87-MG cells and (B) in 
vivo infected subcutaneous U87-MG tumours growing in Hsd:athymic Nude-Foxn1nu mice. DNA was isolated from (A) different 
infection cycles or (B) from infected mice, indicated with numbers at the top of each lane, respectively. Nomenclature of PCR 
fragments is derived from the vector name as follows: the two-letter prefixes AC-, AU-, and AK- denote mutants derived from 
vectors ACE-GFP, ACEU3-GFP, and Akv4070AeGFP or AkvB4070AeGFP, respectively. The subsequent letter or number 
denotes mutants emerging in NIH-3T3 (N), HEK293 (2), U87-MG (U) or solid tumours (T), respectively. The final digit indi-
cates the order of appearance of the PCR-fragment. In the case of revertants composed of more than one deletion, numbers 
and letters describing the participating recombinations are shown. Vector mutants which appear to have arisen consecutively 
contain the name of the putative precursor vector mutant in parentheses. White arrows indicate the size of the PCR product 
resulting from amplification of the respective parental vector. N = DNA from uninfected cultured cells or tumour tissue. 
Empty lanes indicate either that DNA isolation was unsuccessful or that DNA was isolated from tumour tissue apparently not 
infected. M = molecular size marker. Agarose gel images from PCR performed on in vivo infected tumour material 20d post-
infection amended from Journal of Virology, July 2007, p. 6973–6983, Vol. 81, No. 13, doi:10.1128/JVI.02470-06, with permis-
sion from American Society for Microbiology.
Table 1: Distribution of 5' recombination junctions in vector mutants isolated in vitro and in vivo with respect to flanking nucleotide 
sequence homology and EMCV IRES secondary structure
in vitroa in vivob TOTAL
NIH-3T3 HEK293 U87-MG TOTAL
within IRES 2 3 1 6 10 16
pairedc 100 1 78
unpairedd 131 5 38
≥ 4 nt repeate 000 0 00
outside IRES 352 1 0 5 1 5
≥ 4 nt repeat 2 4 1 7 3 10
TOTAL 583 1 6 1 5 3 1
aDistribution of 5' recombination junctions in vector mutants isolated from in vitro infected NIH-3T3, HEK293, and U87-MG cells at the end of each 
cycle
bDistribution of 5' recombination junctions in vector mutants isolated from pre-formed subcutaneous U87-MG tumours growing in nude mice and 
infected in vivo
c5' recombination junctions which fall within paired regions of the EMCV IRES RNA secondary structure [44,67]
d5' recombination junctions which fall within unpaired regions of the EMCV IRES RNA secondary structure [44,67]
e5' recombination junctions which are flanked by nucleotide sequence homology (direct or inverted repeats) of = 4 nt in lengthBMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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in which they emerged, the length and distribution of the
characterised deletions, and the presence of motifs known
to influence retroviral recombination rates (Fig. 4A and
4B). In total, 31 recombination junctions were sequenced,
16 and 15 of which were derived from vector recom-
binants which emerged during in vitro and in vivo experi-
ments, respectively (Fig. 4B, Table 1). Interestingly, several
deletions leading to the emergence of vector recom-
binants were detected repeatedly, not only in both Mo-
MLV-based vectors ACE-GFP and ACEU3-GFP, but also in
different cell lines, both in vitro and in vivo. However, no
common deletion junctions were revealed when the
recombination junctions of vector mutants emerging in in
vitro and in vivo experiments were compared (Fig. 4B).
In in vitro infections, both NIH-3T3 cells transduced with
vector ACE-GFP and HEK293 cells infected with vector
ACEU3-GFP gave rise to vector mutants containing a 90
nucleotide (nt) deletion flanked by a 18 out of 19 nt
imperfect direct repeat in the middle of the eGFP gene
(deletion c, occurring in mutants ACN-2 and AU2-4,
respectively, Fig. 3A and 4B). Another recombination
event which was repeatedly detected in mutants which
emerged in cells infected with the Mo-MLV based vectors
led to the deletion of 75 nts of the U3 region, correspond-
ing to one of the two tandem copies of a transcriptional
enhancer element [41] (deletion b, occurring in mutants
AC2-1+b, AC2-2+b, AU2-1+a+b, AU2-2, AU2-4 and AUN-
1+b, Fig. 3A and 4B), presumably mediated by a 10 nt per-
fect direct repeat flanking the deletion junctions. Interest-
ingly, several of the mutants which were characterised also
revealed a translocation of 81 nts including the T-stretch
[42], the primer binding site and the first 31 nts of the U3
region, leading to the reconstitution of wild type Mo-MLV
LTR sequences (insertion a, occuring in mutants AU2-
1+a+b, AU2-2+a, AU2-3 and AU2-4, Fig. 3A and 4B). Fur-
thermore, mutants which contained deletions associated
with recombination events originating outside of trans-
gene sequences were not confined to non-translated
regions of the MLV genome. In both Mo-MLV-based vec-
tors and also in the N-tropic Akv-MLV-based vector,
recombinants emerged which shared the same 5' deletion
junction, whereby the 3' terminal 11 nts (including the
stop codon) of the env gene were deleted (mutants ACU-
1, AU2-2, and AKN-1, Fig. 3A and 4B).
In several infected cell lines, the emergence of vector
mutants could be detected which appeared to be the prod-
uct of consecutive recombination events. In NIH-3T3 cells
infected with vector ACE-GFP, for example, a recom-
binant (mutant ACN-1) emerged at infection cycle 7, and
seems to have undergone further recombination to gener-
ate a second mutant, ACN-2, which emerged at infection
cycle 13 (Fig. 3A). Similar events could be observed for
vectors ACE-GFP and ACEU3-GFP in HEK293 cells (Fig.
3A).
To provide an overview of the sequence motifs involved in
recombination leading to deletion of transgene sequences
facilitating the emergence of vector mutants, each charac-
terised mutant was classified with respect to position of
the 5' recombination junction, and to the presence of
nucleotide homology and/or RNA secondary structure
[44,67], in sequences flanking the recombination junc-
tions (Table 1). The majority of all characterised deletion
mutants containing the 5' deletion junction in non-IRES
sequences were flanked by direct repeats, whereas all of
the mutants containing the 5' junction within the IRES
sequence were mediated by non-homologous recombina-
tion (Table 1). No differences concerning the types of
recombination events leading to the emergence of vector
mutants between vectors of different strain or transgene
insert position could be discerned, however.
Of the sequenced deletion junctions derived from
mutants which emerged during in vitro experiments, 6
(37.5%) involved 5' recombination sequences within the
EMCV IRES RNA and 10 (62.5%) used 5' recombination
sequences in non-IRES sequences, of which 7 were
flanked by perfect or imperfect direct repeats of 4 nts or
longer (Table 1). Of the 6 deletion junctions which used
5' recombination sequences within the IRES, 5 had 5'
junctions positioned within an unpaired region of the
RNA secondary structure [43,44,67] and were formed pre-
dominantly via non-homologous recombination (Table
1). Of the 15 junctions derived from vector mutants
which emerged in infected tumours, 10 utilised 5' recom-
bination sequences within the EMCV IRES and 5 used 5'
recombination sequences in non-IRES sequences, of
which 3 involved identical perfect direct repeats of 10 nts
(mutants AUT-3, AUT-5 and AUT-8, Fig. 3B and 4B, Table
1). Interestingly, of the 10 vector mutants which emerged
in vivo containing 5' recombination junctions positioned
in the IRES, only 3 contained the 5' recombination junc-
tion within an unpaired region of the IRES RNA secondary
structure, suggesting that the precise mechanisms leading
to the emergence of vector mutants in cell culture and in
solid tumours may differ.
Discussion
A number of MLV-based RCR vector designs which hold
great promise for use in cancer gene therapy applications
have recently been described, demonstrating a therapeutic
efficacy in experimental tumours far exceeding that of
equivalent replication-deficient vectors (for review see
[45]). High genomic stability, however, is of central
importance for the future clinical success of RCR vectors,
since only dissemination of the intact transgene cassetteBMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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Figure 4 (see legend on next page)
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to the entire tumour mass can guarantee that each malig-
nant cell will be exposed to the therapeutic effect.
Thus, in the present study, we analysed the rate of emer-
gence of vector recombinants in cells and solid tumours
infected with a panel of MLV-based RCR vectors of differ-
ent designs, and characterised the molecular mechanisms
involved in the associated recombination processes. In
general, the rate of emergence of predominating vector
recombinants correlated with the reduction in the per-
centage of eGFP-positive cells during iterative propaga-
tion cycles of the respective vectors on cultured cells (Fig.
2A) [35].
The greatly superior genomic stability of vectors contain-
ing an IRES-eGFP cassette fused to the 3' end of the env
gene compared to when inserted into the U3 region of the
3' LTR is likely due to insertion of the transgene in the U3
region impairing virus replication to a greater extent.
Reasons for the observed differences in the genomic sta-
bility of vectors based on different MLV strains and in dif-
ferent cell types are more ambiguous. Seemingly the most
obvious reason for decreased genomic stability of an
MLV-based RCR vector in NIH-3T3 cells would be recom-
bination with an endogenous retrovirus, as has been pre-
viously reported in studies of MLV-based RCR vectors
containing ecotropic env genes [46]. However, sequencing
of the recombination junctions of vector mutants did not
reveal any role for this in the present study, perhaps
because the amphotropic env  gene was used. Ampho-
tropic envelope sequences are not present in the Mus
germ line [47] and hence, presumably, vectors containing
the amphotropic env gene are less likely to recombine via
homologous recombination with endogenous env
sequences than vectors containing ecotropic env  genes.
On the other hand, it is important to bear in mind that
only recombinants which maintain binding sites for the
PCR primers will be detected, hence, recombinants which
may contribute to the overall instability of the replicating
viral vector population may have been overlooked by the
PCR-based assay used in this study. In addition, if recom-
bination events did indeed occur with endogenous env
sequences, it is possible that the resulting recombinant
vectors would also remain undetected within the replicat-
ing viral population. This would also, presumably, be
more likely to occur with Akv-MLV based vectors, since
Akv-MLV is itself a member of the closely related ecotropic
MLV family.
At first glance, it would also appear that the genomic sta-
bility of vectors decreases as a function of their replication
kinetics in a particular cell line, since, as previously
described, all vectors replicate most rapidly in NIH-3T3
cells, in which they are also the least stable [35]. However,
this would not explain the differences, for example, in the
stability of vectors ACEU3-GFP or Akv(B)4070AeGFP in
U87-MG and HEK-293 cells, in which their replication
kinetics are more similar to each other. Moreover, we have
also performed studies in human HepG2 cells [24], where
we also found vector ACE-GFP to be much less stable
when compared to the results obtained here in U87-MG
and HEK-293 cells, in spite of the fact that ACE-GFP rep-
lication kinetics in HepG2 cells are similar to, or slower,
than in HEK-293 cells. Hence, the reasons for the differ-
ences in vector genomic stability between cell lines seems
to be neither species specific nor directly related to the dif-
ferent replication kinetics of the vectors in the respective
cell lines.
The observed differences in vector stability in different cell
lines could, on the other hand, potentially be due to dif-
ferences in other virus and/or host-cell features. The
intrinsic fidelity of the RT of the Akv and Moloney strains
of MLV for example, and/or their nucleocapsid (NC) pro-
teins may differ in the efficiency of modulating the reverse
transcription reaction, as has been demonstrated for the
RT from different types of retrovirus [48-51]. Cellular
Distribution and sequence analysis of vector recombinants Figure 4 (see previous page)
Distribution and sequence analysis of vector recombinants. (A) Schematic representation of vector mutants detected 
by PCR using primers annealing in the MLV 4070A env and eGFP gene indicating the distribution of the deleted sequences. 
Numbers indicate distances of vector border regions from the 5' end of the IRES. Annealing positions of sequencing primers 
are indicated by black arrows. Coloured horizontal lines indicate the positions of single deleted sequences in mutants isolated 
from in vitro infected cell lines (NIH-3T3 (blue), HEK293 (red), U87-MG (green)) and from in vivo infected U87-MG tumours 
(black). (B) Sequence analysis of deletion junctions. Nomenclature of the PCR products is according to Fig. 3. Intact (capital 
letters) and deleted sequences (lower case letters) are separated by vertical text indicating the regions where the deletions 
occurred. Bold numbers display the distances of the 5' and 3' deletion junctions from the 5' end of the IRES, which is set as 1. 
Lengths (nt) of deleted regions are indicated by a delta symbol. Repeats flanking the deleted sequences are indicated by under-
lined letters (continuous lines represent direct repeats, dotted lines represent inverted repeats). a* = insertion of 81 nt repre-
senting the 5' part of the 3' LTR U3 region, translocated from the 5' end of the transgene cassette and reconstituting the U3 
region, b** = recurring 75 nt deletion occurring in the U3 region, detected in recombinants AC2-1, AC2-2, AU2-1, AU2-3, 
AU2-4, and AUN-1, c*** = 90 nt deletion found in mutant vectors ACN-2 and AU2-4.BMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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RNAP II, which synthesizes the retroviral genome, has
also been demonstrated to introduce mutations and/or
deletions into retroviral vector genomes, albeit at a low
frequency [7], and it is possible that some cell line specific
differences in the fidelity of this process exist. Addition-
ally, p53 expression has been shown to be able to provide
a proof-reading function for reverse transcriptase [52-54],
and it is possible that this could also play a role in the dif-
ferences in genomic stability of vectors in different cell
lines, as could also be hypothesized for differences in the
expression of host-encoded anti-viral mechanisms such as
APOBEC and TRIM family members [55-58]. Host cell-
specific differences in vector genomic stability could also
be influenced by the availability and balance of intracellu-
lar dNTP pools, as described for cells with low metabolic
activity or under hypoxic conditions, since it is known
that this can decrease the processivity of RT and concom-
itantly increase the frequency of RT-pausing and recombi-
nation [59-61], as can low temperatures [62,63].
Vector genome motifs which have been demonstrated to
increase the frequency of recombination events include
nucleotide sequence homology (direct and indirect
repeats) [36,37], homopolymeric sequences [64-66], and
RNA secondary structure [38-40]. In the present study,
PCR and sequencing of vector mutants emerging in
infected cells and tumours revealed that the majority of
vector deletions in which the 5' deletion junction was
positioned in non-IRES sequences were flanked by direct
repeats (Fig. 4B, Table 1). These results underpin those of
Logg and colleagues, who found that all sequenced vector
mutants emerging in Mo-MLV-based RCR vectors contain-
ing transgene cassettes in the 3' UTR were associated with
flanking nucleotide homology [46]. Moreover, our results
revealed no virus-strain specific transgene deletion mech-
anism bias, which is important, since the only other study
on recombination events in RCR vectors utilised the Akv
strain of MLV [67]. In this study, the authors detected an
RNA secondary structure bias for recombination events
leading to the emergence of vector mutants, albeit only
deletion mutants with 5' recombination junctions in the
EMCV IRES were taken into account. In the present study,
we also found that the majority of 5' recombination junc-
tions positioned in the EMCV IRES in vector mutants
emerging in cell culture were located in unpaired regions
of RNA, underpinning the results of Duch and colleagues,
and demonstrating that this observation is not restricted
to the Akv strain of MLV. Interestingly, however, only 30%
of the 5' recombination junctions within the IRES
sequence were positioned in unpaired RNA secondary
structures in the analysed vector mutants emerging in vivo,
in contrast to over 75% in cell culture, when our studies
and those of others [46,68] are combined. This result sug-
gests that there may be differences in the mechanisms
leading to the emergence of recombinant vectors in cell
culture and solid tumours. However, although we
sequenced and analysed the vast majority of deletion
mutants which we could detect by PCR in this study,
amounting to a total of 15 vector mutants detected in 45
xenograft tumours, this conclusion remains tentative due
to the relatively small number of recombination events
which we could analyse. It remains to be seen whether our
observations will be supported by data arising from future
analyses of RCR vectors in solid tumours.
Common recombinant junctions were invariably associ-
ated with flanking nucleotide sequence homology, either
within the eGFP gene, or within the U3 region of the Mo-
MLV LTR, whereby the latter was involved in the genera-
tion of mutants lacking one copy of a tandem enhancer
sequence [41]. While it is not expected that the deletion of
viral sequences should generate mutants of increased rep-
licative fitness, spontaneous enhancer deletions have pre-
viously been described [69], and it may be that a second
copy of the enhancer sequence is redundant for efficient
replication in certain cell types.
Interestingly, in both Mo-MLV- and Akv-MLV-based vec-
tors, deletion mutants emerged in which short sequences
at the 3' end of the env gene were deleted, resulting either
in truncated or elongated Env proteins. It has previously
been demonstrated that short truncations of the C-termi-
nus of the Env protein have no impact on cell-cell fusion
or viral transduction [70] and that the actual composition
of the R-peptide, located at the very C-terminal end of the
Env protein, has minimal effect on the inhibition of its
fusogenic potential [71]. Hence it can be assumed that the
relatively short truncations and elongations of the Env
protein resulting from the deletions observed in this study
also had no detrimental effect on the replicative fitness of
the affected mutants. A further unusual recombination
event, occurring in vector ACEU3-GFP, involved the trans-
location of 81 nts of the 3' UTR and U3 region, and led to
the reconstitution of a wild type Mo-MLV LTR, indicating
that the reduced genomic stability of ACEU3-GFP com-
pared to ACE-GFP may be a result of the interruption of
the spatial integrity of the 3' UTR and U3 region by the
IRES-eGFP cassette. Such translocation events leading to
restoration of wild-type retroviral LTRs have been previ-
ously described for U3-deleted SNV vectors, where it was
shown that vectors with a deleted 3' LTR U3 region under-
went recombination between the 5' and 3' LTRs to restore
wild-type U3 sequences in both LTRs [72].
Conclusion
Taken together, our data provide additional evidence that
the high selection pressure imposed on MLV-based RCR
vectors to delete transgenic sequences which interfere
with their replication kinetics can be overcome to an
extent by using appropriate vector designs. Clearly, resultsBMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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obtained using a non-therapeutic marker gene such as
eGFP in cell culture or in tumour models in nude mice do
not truly reflect the situation which will be encountered in
a therapeutic situation in immunocompetent patients.
The potential effects of therapeutic transgene toxicity and
immunogenicity, as well as additional unpredictable
influences of specific transgene sequences on RCR replica-
tion kinetics and genomic stability, must therefore be
determined on a case-by-case basis in cell culture and ani-
mal models before embarking on a clinical study. This
notwithstanding, the PCR, sequencing and real time PCR/
RT-PCR analyses in the present study strongly support the
hypotheses suggested by our analyses of functional trans-
gene propagation [35], that MLV-based RCR vectors based
on the Moloney strain of MLV and containing the trans-
gene cassette in the 3' UTR region are more suitable for
potential cancer gene therapy applications than those
based on Akv-MLV and/or containing the transgene cas-
sette in the U3 region of the LTR. Our findings that, in cell
culture, deletion mutants which emerge are generally
associated with nucleotide homology or unpaired regions
of RNA secondary structure reinforces similar observa-
tions obtained from more delimited studies of recombi-
nation mechanisms associated with MLV-based RCR
vectors [46,68], indicating that vector stability could pos-
sibly be further improved by reducing the frequency of
such motifs in the transgene cassette. Moreover, to our
knowledge, this is the first study which has investigated
the underlying mechanisms associated with transgene
deletion in RCR vector recombinant emergence in vivo,
and the discrepancies between the data obtained in solid
tumours in vivo and our own and previously published
data from infected cells in vitro demonstrates the impor-
tance of evaluating vectors designed for use in cancer gene
therapy in vivo as well as in vitro.
Methods
Plasmids, cell culture and virus production
Plasmids pACE-GFP [22], pACEU3-GFP,
pAkv4070AeGFP and pAkvB4070AeGFP [35], encoding
replication-competent retroviral vectors of different strain
and transgene insertion site were used for transient trans-
fection of HEK293 cells (ATCC CRL-1573) to produce
viral vector stocks as described previously [35]. The B-
tropic vector pAkvB4070AeGFP differs from N-tropic vec-
tor pAkv4070AeGFP only by a Glu to Arg transition in the
capsid protein, permitting efficient infection of human
cells.
Subsequent infection cycles on HEK293 cells, NIH-3T3
cells (ATCC CRL-1658) and U87-MG cells (ATCC HTB-
14) were performed as previously described [35]. Briefly,
cells were transduced with the respective vectors at an
multiplicity of infection (MOI) of 0.001 to initiate infec-
tion cycle 1, two days later the infected cells were passaged
1:3, and an aliquot was used to measure enhanced green
fluorescence protein (eGFP) expression via fluorescence
activated cell sorting (FACS). Four days post infection
serial dilutions of supernatant from infected cells were
used to initiate infection cycle 2. Cells infected with a dilu-
tion allowing exponential vector spread up to 4 days post
infection were used to continue the experiment. Infected
cells were passaged every 2 or 3 days until the percentage
of eGFP-positive cells ceased to increase from one passage
to the next. Serial infection cycles were continued in this
manner until less than 2% of infected cells became eGFP-
positive following serial passaging. At the end of each
infection cycle, cell-free virus-containing supernatants
and cell pellets were stored by freezing at -80°C.
For in vivo infection, preformed U87-MG subcutaneous
tumours growing in 4-week-old male Hsd:athymic Nude-
Foxn1nu mice (Harlan) were used, as described previously
[35]. All animal experiments were discussed and
approved by the institutional ethics committee (GZ
68.205/53-BrGt/2004). Briefly, at a tumour size of 60 to
100 mm3, normally three to four weeks after cell injec-
tion, 1 × 105 viral particles suspended in 20 μl Dulbecco's
modified Eagles medium (DMEM, Invitrogen) were
injected directly into the tumour centre. Five mice per vec-
tor and time point were sacrificed 5, 10, and 20 days post
infection, and tumours were excised and used for further
analysis.
Real-time PCR, real-time RT-PCR, and PCR analysis
Genomic DNA and viral RNA was extracted from infected
cells and tumour tissue, and from virus-containing super-
natants, respectively, using the DNeasy Tissue Kit (Qia-
gen) or the Viral RNA Kit (Qiagen) as recommended by
the manufacturer. PCR amplification of vector sequences
was performed using primers annealing to sequences in
the amphotropic MLV 4070A env gene and in the 3'-LTR
[35]. Real-time PCR and real-time RT-PCR was performed
using primers and probes annealing either to sequences in
the 4070A env gene or in the encephalomyocarditis virus
(EMCV) internal ribosome entry site (IRES) or the eGFP
gene. Primers and probes were designed with Primer
Express 3.0 software (PE Applied Biosystems) and synthe-
sized by Microsynth. Primers and probes annealing to
eGFP and env gene sequences have been described previ-
ously [35,73]. For detection of IRES-specific sequences,
primers IRES-F (5'-AACAACGTCTGTAGCGACCCTT-3')
and IRES-R (5-GCCGCCTTTGCAGGTGTAT-3'), and
probe IRES-P (5'-CTGGCGACAGGTGCCTC TGCG-3')
were used. Real-time PCR and real-time RT-PCR reactions
were performed as described elsewhere [73].
Sequence analyses
PCR products were separated by agarose gel electrophore-
sis, isolated and purified from the agarose gel using theBMC Molecular Biology 2009, 10:8 http://www.biomedcentral.com/1471-2199/10/8
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QIAquick Gel Extraction Kit (Qiagen) according to the
manufacturer's protocol, and either sequenced directly
using primers employed for genomic DNA amplification,
as described above, or subcloned into vector pCR2.1 (Inv-
itrogen) and sequenced using standard primers M13 for-
ward (5'-TTCCCAGTCACGACGTTG-3') and M13 reverse
(5'-CACACAGGAAACAGCTATGACC-3').
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